La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Lincoln Pharmaceuticals Gestione

Gestione criteri di controllo 4/4

Lincoln Pharmaceuticals' Il CEO è Mahendrabhai Patel, nominato in Jun2018, e ha un mandato di 6.17 anni. la retribuzione annua totale è ₹ 3.32M, composta da 99.1% di stipendio e 0.9% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 8.18% delle azioni della società, per un valore di ₹ 1.18B. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 9 anni e 19.4 anni.

Informazioni chiave

Mahendrabhai Patel

Amministratore delegato

₹3.3m

Compenso totale

Percentuale dello stipendio del CEO	99.1%
Mandato del CEO	6.3yrs
Proprietà del CEO	8.2%
Durata media del management	9.1yrs
Durata media del Consiglio di amministrazione	19.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Do Lincoln Pharmaceuticals' (NSE:LINCOLN) Earnings Warrant Your Attention?

Sep 06

Lincoln Pharmaceuticals Limited's (NSE:LINCOLN) Business And Shares Still Trailing The Market

Mar 14

If You Like EPS Growth Then Check Out Lincoln Pharmaceuticals (NSE:LINCOLN) Before It's Too Late

Feb 14

Should You Be Adding Lincoln Pharmaceuticals (NSE:LINCOLN) To Your Watchlist Today?

Aug 16

Here's Why I Think Lincoln Pharmaceuticals (NSE:LINCOLN) Is An Interesting Stock

May 06

Is Lincoln Pharmaceuticals Limited (NSE:LINCOLN) A Smart Choice For Dividend Investors?

Apr 03

Does Lincoln Pharmaceuticals (NSE:LINCOLN) Have A Healthy Balance Sheet?

Mar 15

Could The Market Be Wrong About Lincoln Pharmaceuticals Limited (NSE:LINCOLN) Given Its Attractive Financial Prospects?

Feb 28

Insider Buying: The Lincoln Pharmaceuticals Limited (NSE:LINCOLN) Whole Time Director Just Bought 15% More Shares

Feb 12

Does Lincoln Pharmaceuticals (NSE:LINCOLN) Deserve A Spot On Your Watchlist?

Feb 01

Lincoln Pharmaceuticals (NSE:LINCOLN) Shareholders Booked A 27% Gain In The Last Five Years

Jan 19

Trade Alert: The Whole Time Director Of Lincoln Pharmaceuticals Limited (NSE:LINCOLN), Munjal Patel, Has Just Spent ₹20m Buying 9.2% More Shares

Jan 06

Why Lincoln Pharmaceuticals Limited (NSE:LINCOLN) Is A Dividend Rockstar

Dec 27

Lincoln Pharmaceuticals's (NSE:LINCOLN) Earnings Are Growing But Is There More To The Story?

Dec 14

Have Insiders Been Buying Lincoln Pharmaceuticals Limited (NSE:LINCOLN) Shares This Year?

Dec 01

Declining Stock and Solid Fundamentals: Is The Market Wrong About Lincoln Pharmaceuticals Limited (NSE:LINCOLN)?

Nov 18

Is Lincoln Pharmaceuticals (NSE:LINCOLN) A Risky Investment?

Nov 05

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Mahendrabhai Patel rispetto agli utili di Lincoln Pharmaceuticals?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	₹980m
Mar 31 2024	n/a	n/a	₹933m
Dec 31 2023	n/a	n/a	₹873m
Sep 30 2023	n/a	n/a	₹808m
Jun 30 2023	n/a	n/a	₹769m
Mar 31 2023	₹3m	₹3m	₹729m
Dec 31 2022	n/a	n/a	₹714m
Sep 30 2022	n/a	n/a	₹674m
Jun 30 2022	n/a	n/a	₹667m
Mar 31 2022	₹3m	₹3m	₹694m
Dec 31 2021	n/a	n/a	₹709m
Sep 30 2021	n/a	n/a	₹668m
Jun 30 2021	n/a	n/a	₹647m
Mar 31 2021	₹3m	₹3m	₹623m
Dec 31 2020	n/a	n/a	₹586m
Sep 30 2020	n/a	n/a	₹560m
Jun 30 2020	n/a	n/a	₹540m
Mar 31 2020	₹2m	₹2m	₹514m
Dec 31 2019	n/a	n/a	₹510m
Sep 30 2019	n/a	n/a	₹492m
Jun 30 2019	n/a	n/a	₹453m
Mar 31 2019	₹2m	₹2m	₹487m
Dec 31 2018	n/a	n/a	₹470m
Sep 30 2018	n/a	n/a	₹495m
Jun 30 2018	n/a	n/a	₹458m
Mar 31 2018	₹2m	₹2m	₹346m

Compensazione vs Mercato: La retribuzione totale di Mahendrabhai ($USD 39.58K ) è inferiore alla media delle aziende di dimensioni simili nel mercato Indian ($USD 179.15K ).

Compensazione vs guadagni: La retribuzione di Mahendrabhai è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Mahendrabhai Patel (70 yo)

6.3yrs

Mandato

₹3,322,000

Compensazione

Mr. Mahendrabhai Gulabdas Patel, B.A, LLB serves as Managing Director of Lincoln Pharmaceuticals Ltd. Mr. Patel has varied experience of chemicals, steel, finance etc. Mr. Patel handles corporate planning...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Mahendrabhai Patel	MD & Whole Time Director	6.3yrs	₹3.32m	8.18% ₹ 1.3b
Darshit Shah	Chief Financial Officer	5.5yrs	₹1.18m	Nessun dato
Trusha Shah	Company Secretary & Compliance Officer	1.8yrs	₹228.00k	Nessun dato
Ashish Patel	Head of Sales & Marketing and Whole Time Director	11.9yrs	₹53.35k	10.6% ₹ 1.6b
Hashmukhbhai Patel	Whole Time Director	29.7yrs	₹3.33m	1.87% ₹ 288.8m
Munjal Patel	Whole Time Director	no data	₹3.44m	13.37% ₹ 2.1b
Sanjay Bhatt	Senior Manager of Operation	no data	Nessun dato	Nessun dato
C. Kapadia	Head of Sales & Admin	no data	Nessun dato	Nessun dato
Amit Dwivedi	Group Marketing Manager	no data	Nessun dato	Nessun dato
Sachin Kapoor	Head of H R D	no data	Nessun dato	Nessun dato
K. Sompura	Head of Finance	no data	Nessun dato	Nessun dato
Dhaval Gandhi	Head of Information Technology	20.7yrs	Nessun dato	Nessun dato

9.1yrs

Durata media

49yo

Età media

Gestione esperta: Il team dirigenziale di LINCOLN è esperto e expertise (durata media dell'incarico 9 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Mahendrabhai Patel	MD & Whole Time Director	29.7yrs	₹3.32m	8.18% ₹ 1.3b
Ashish Patel	Head of Sales & Marketing and Whole Time Director	9.8yrs	₹53.35k	10.6% ₹ 1.6b
Hashmukhbhai Patel	Whole Time Director	29.7yrs	₹3.33m	1.87% ₹ 288.8m
Munjal Patel	Whole Time Director	9.8yrs	₹3.44m	13.37% ₹ 2.1b
Rajnikant Patel	Non-Executive Director	29.7yrs	Nessun dato	3.78% ₹ 584.9m
Kishorbhai Shah	Non-Executive Chairman	29.1yrs	Nessun dato	2.39% ₹ 369.8m
Saurin Jagdish Parikh	Independent Non-Executive Director	6.5yrs	Nessun dato	Nessun dato
Nareshkumar Suthar	Independent Director	no data	Nessun dato	Nessun dato
Seema Mehta	Woman Independent Director	less than a year	Nessun dato	Nessun dato

19.5yrs

Durata media

66yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di LINCOLN è composto da personale esperto e esperto (durata media dell'incarico 19.4 anni).

Lincoln Pharmaceuticals Gestione

Gestione criteri di controllo 4/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Lincoln Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2024

Lincoln Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2024

Whole Time Director recently bought ₹20m worth of stock

Lincoln Pharmaceuticals Limited Announces Resignation of Meha Patel as Non-Executive Independent women Director

Insider recently bought ₹13m worth of stock

Whole Time Director recently bought ₹15m worth of stock

Recent updates

Do Lincoln Pharmaceuticals' (NSE:LINCOLN) Earnings Warrant Your Attention?

Dividend increased to ₹1.80

Lincoln Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2024

Lincoln Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2024

First quarter 2025 earnings released: EPS: ₹11.82 (vs ₹9.49 in 1Q 2024)

Lincoln Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 08, 2024

Lincoln Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 08, 2024

Whole Time Director recently bought ₹20m worth of stock

Full year 2024 earnings released: EPS: ₹46.58 (vs ₹36.40 in FY 2023)

Lincoln Pharmaceuticals Limited Recommends Dividend for the Year Ended March 31, 2024

New minor risk - Insider selling

Now 20% overvalued

Now 22% overvalued

Now 24% overvalued

Lincoln Pharmaceuticals Limited's (NSE:LINCOLN) Business And Shares Still Trailing The Market

Investor sentiment improves as stock rises 15%

Lincoln Pharmaceuticals Limited Announces Resignation of Meha Patel as Non-Executive Independent women Director

Insider recently bought ₹13m worth of stock

Third quarter 2024 earnings released: EPS: ₹14.00 (vs ₹10.79 in 3Q 2023)

Lincoln Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 08, 2024

Does Lincoln Pharmaceuticals (NSE:LINCOLN) Deserve A Spot On Your Watchlist?

Second quarter 2024 earnings released: EPS: ₹13.81 (vs ₹11.84 in 2Q 2023)

Lincoln Pharmaceuticals Limited Declares Dividend for the Financial Year 2022-23

Lincoln Pharmaceuticals' (NSE:LINCOLN) Dividend Will Be ₹1.50

Upcoming dividend of ₹1.50 per share at 0.3% yield

Lincoln Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 14, 2024

Lincoln Pharmaceuticals (NSE:LINCOLN) Is Paying Out A Dividend Of ₹1.50

Whole Time Director recently bought ₹15m worth of stock

First quarter 2024 earnings released: EPS: ₹9.49 (vs ₹7.49 in 1Q 2023)

Whole Time Director recently bought ₹15m worth of stock

Full year 2023 earnings released: EPS: ₹36.40 (vs ₹34.63 in FY 2022)

Lincoln Pharmaceuticals Limited Approves the Resignation of Anand A. Patel from the Position of Whole Time Director as Well as Director of the Company

Investor sentiment improves as stock rises 15%

Lincoln Pharmaceuticals Limited to Report Q4, 2023 Results on May 25, 2023

Whole Time Director recently bought ₹5.0m worth of stock

Third quarter 2023 earnings released: EPS: ₹10.79 (vs ₹8.79 in 3Q 2022)

Lincoln Pharmaceuticals Limited to Report Q3, 2023 Results on Feb 09, 2023

Lincoln Pharmaceuticals Limited Informs About Demise of Shri Ishwarlal Ambalal Patel Independent Director

MD & Whole Time Director recently bought ₹20m worth of stock

MD & Whole Time Director recently bought ₹9.9m worth of stock

Less than half of directors are independent

Lincoln Pharmaceuticals Limited Appoints Trusha Shah as Company Secretary and Compliance Officer

Lincoln Pharmaceuticals Limited Approves to Declare Dividend for the Financial Year 2021-22

Lincoln Pharmaceuticals' (NSE:LINCOLN) Dividend Will Be ₹1.50

Upcoming dividend of ₹1.50 per share

Lincoln Pharmaceuticals Limited Proposes to Declare Dividend for the Financial Year 2021-2022

Lincoln Pharmaceuticals Limited Proposes to Declare Dividend for the Financial Year 2021-2022

Lincoln Pharmaceuticals (NSE:LINCOLN) Is Due To Pay A Dividend Of ₹1.50

Lincoln Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2022

Lincoln Pharmaceuticals Limited Approves Appointment of Anand A. Patel as an Additional and Whole Time Director

First quarter 2023 earnings released: EPS: ₹7.49 (vs ₹8.85 in 1Q 2022)

Lincoln Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 09, 2022

Lincoln Pharmaceuticals Limited Announces Resignation of Niren A. Desai as Company Secretary / Compliance Officer, with Effect from July 19, 2022

Board Member recently bought ₹20m worth of stock

Whole Time Director recently bought ₹20m worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Lincoln Pharmaceuticals Limited Recommends Dividend for the Year Ended March 31, 2022

Less than half of directors are independent

Whole Time Director recently bought ₹6.0m worth of stock

If You Like EPS Growth Then Check Out Lincoln Pharmaceuticals (NSE:LINCOLN) Before It's Too Late

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Lincoln Pharmaceuticals Limited to Report Q3, 2022 Results on Feb 10, 2022

Board Member recently bought ₹8.2m worth of stock

Lincoln Pharmaceuticals Limited (BSE:531633) acquired plant in Mehsana, Gujarat for INR 300 million.

MD & Whole Time Director recently bought ₹15m worth of stock

Investor sentiment improved over the past week

Board Member recently bought ₹11m worth of stock

Whole Time Director recently bought ₹12m worth of stock

Should You Be Adding Lincoln Pharmaceuticals (NSE:LINCOLN) To Your Watchlist Today?